Physician profile
Richard Sadowitz
NPI 1639175631
$16,145.18
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,882 · 2020: $1,992 · 2021: $3,094 · 2022: $3,982 · 2023: $2,840 · 2024: $2,355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,194.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,570.83 | 2019-2024 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,127.82 | 2019-2024 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $1,303.20 | 2019-2024 | Stelara, Simponi Aria, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $751.34 | 2019-2024 | Entyvio, Eohilia, Gattex |
| Janssen Scientific Affairs, LLC | $594.75 | 2019-2022 | |
| Daiichi Sankyo INC. | $553.03 | 2019-2023 | Injectafer |
| Nestle Healthcare Nutrition INC. | $406.55 | 2020-2023 | |
| Allergan, INC. | $374.28 | 2019-2020 | |
| Redhill Biopharma INC. | $366.45 | 2020-2024 | Talicia |
| Merck Sharp & Dohme LLC | $361.29 | 2019-2024 | Dificid |
| Intra-Sana Laboratories | $326.35 | 2022-2024 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Regeneron Healthcare Solutions, INC. | $269.57 | 2022-2024 | Dupixent |
| Pfizer INC. | $262.39 | 2019-2021 | |
| Ardelyx, INC. | $256.16 | 2022-2023 | Ibsrela |
| Genzyme Corporation | $234.54 | 2022-2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $220.84 | 2024 | Voquezna |
| Braintree Laboratories, INC. | $180.35 | 2019-2024 | Sutab, Suflave |
| Ironwood Pharmaceuticals, INC | $175.24 | 2019-2024 | Linzess |
| Intercept Pharmaceuticals, INC. | $142.88 | 2020-2023 | Ocaliva |
| Lilly USA, LLC | $137.20 | 2024 | Omvoh |
| Ferring Pharmaceuticals INC. | $76.59 | 2019-2022 | |
| Evoke Pharma, INC. | $65.52 | 2020-2021 | |
| Boston Scientific Corporation | $61.22 | 2020-2023 | |
| Romark Laboratories, Lc | $56.09 | 2020 | |
| Celgene Corporation | $53.46 | 2021-2022 | |
| Medtronic, INC. | $51.36 | 2021-2022 | |
| Ucb, INC. | $50.75 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $35.84 | 2024 | Iqirvo, Bylvay |
| Alnylam Pharmaceuticals INC. | $27.41 | 2021 | |
| Gilead Sciences, INC. | $22.35 | 2020 | |
| Qol Medical, LLC | $16.40 | 2021 | |
| Shionogi INC | $13.13 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Sadowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.